2022³â ´ëÇѽɺÎÀüÇÐȸ ÇÏ°è ½ÉÆ÷Áö¾ö : 2022-06-11±³À°ÀÏÀÚ : 2022-06-11
±³À°Àå¼Ò : ´ë±¸ ÀÎÅͺҰí È£ÅÚ 1Ãþ Áñ°Å¿îȦ
±³À°ÁÖÁ¦ :
2022³â ´ëÇѽɺÎÀüÇÐȸ ÇÏ°è ½ÉÆ÷Áö¾öÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѽɺÎÀüÇÐȸ
´ã´çÀÚ : °°æ·¡
¿¬¶ôó : 02-3275-5335
À̸ÞÀÏ :
khfs3@khfs.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 80¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
´ë±¸±¤¿ª½Ã±³À°½Ã°£ : 7 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í »çÀüµî·Ï : ÀüÀÓÀÇ, ÀÓ»ó°»ç(10,000¿ø) /Àü°øÀÇ, °£È£»ç, Á¦¾à»ç, ±× ¿Ü ÀÇ·áÁ¾»çÀÚµé(¹«·á) ÇöÀåµî·Ï : Àü¹®ÀÇ(50,000¿ø), ÀüÀÓÀÇ, ÀÓ»ó°»ç(20,000¿ø) / Àü°øÀÇ, °£È£»ç, Á¦¾à»ç, ±× ¿Ü ÀÇ·áÁ¾»çÀÚµé(10,000¿ø)
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 09:00~09:15 Diagnostic conundrums in Heart Failure with Preserved Ejection Fraction, is ejection fraction enough? ½ÉÁö¿µ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 09:15~09:30 The conundrum of patients with obesity, exercise intolerance, elevated ventricular filling pressures in normal ejection fraction. Which medications are needed for them? How about weight reduction? ±èÁöÈñ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 09:30~09:45 The burden of apical hypertrophic cardiomyopathy with elevated ventricular filling pressures. What should we do for them? ±è´Ù·¡(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 09:45~10:00 Who is the Best Candidate for Sodium glucose cotransporter 2 inhibitor in patients with Heart Failure with Preserved Ejection Fraction? ÀÌÂùÁÖ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 10:00~10:15 Molecular mechanism of heart failure: What is the next therapeutic target? À̼ö¿ë(ºÎ»êÀÇ´ë)
Åä·Ð 06-11 Áñ°Å¿îȦ 10:15~10:40 Discussion ´Ù°»ç(´Ù¼Ò¼Ó)
ÈÞ½Ä 06-11 Áñ°Å¿îȦ 10:40~10:50 Coffee Break ()
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 10:50~11:05 Laboratory testing: Gene panels to whole genome sequencing ±ââ¼®(GCÁö³ð)
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 11:05~11:20 Hypertrophic cardiomyopathy: Monogenetic heart disease: When is a genetic variant disease-causing? ÃÖÀÇ¿µ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 11:20~11:35 Arrhythmogenic cardiomyopathies ±è°æÈñ(ÀÎõ ¼¼Á¾º´¿ø)
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 11:35~11:50 Genetics of dilated cardiomyopathy: practical implications ¿ÀÀç¿ø(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 11:50~12:05 (How to find significant genetic variations in rare disease like paraaminohippuric acid? ÃÖÁ¤¹Î(°í·ÁÀÇ´ë)
Åä·Ð 06-11 Áñ°Å¿îȦ 12:05~12:30 Discussion ´Ù°»ç(´Ù¼Ò¼Ó)
ÈÞ½Ä 06-11 Áñ°Å¿îȦ 12:30~13:20 Lunch Time ()
ÈÞ½Ä 06-11 Áñ°Å¿îȦ 13:20~13:30 Break for Quarantine ()
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 13:30~13:45 Influence of surgical techniques and other factors on successful Management Control System outcomes Á¶¾çÇö(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 13:45~14:00 Minimizing and treating complications in left ventricular assist device patients- bleeding to infection Ȳȣ¿µ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 14:00~14:15 Strategies to prevent fraility and deconditioning before and after left ventricular assist device ÀÌÇý¿ø(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 14:15~14:30 Optimized medical treatment in left ventricular assist device ÇöÁØÈ£(¿ï»êÀÇ´ë)
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 14:30~14:45 Chronic management in mechanical circulatory support ±èÀÎö(°è¸íÀÇ´ë)
Åä·Ð 06-11 Áñ°Å¿îȦ 14:45~15:10 Discussion ´Ù°»ç(´Ù¼Ò¼Ó)
ÈÞ½Ä 06-11 Áñ°Å¿îȦ 15:10~15:30 Coffee Break ()
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 15:30~16:00 Cardiac amyloidosis ÀüÀº¼®(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 16:00~16:20 Case 1 (È£Èí°ï¶õÀÌ ¾ÇȵǾî ÀÇ·ÚµÈ Ç×ÀÎÁöÁúÁõÈıºÀ» °¡Áø 41¼¼ ¿©ÀÚ È¯ÀÚ) ±èºÀÁØ(°í½ÅÀÇ´ë)
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 16:20~16:40 Case 2 (Severe Infection After Heart Transplantation) À±¹ÎÀç(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 16:40~17:00 Case 3 (Myocarditis Combined With Acute Myocardial Infarction) À̼ö¿¬(ÀÎõ ¼¼Á¾º´¿ø)
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 17:00~17:20 Case 4 ("Advanced heart failure with impending End-stage renal disease : early dialysis vs. late dialysis") Àü°æÇö(±¹¹Î°Ç°º¸Çè Àϻ꺴¿ø)
±³À°½Ã°£ 06-11 Áñ°Å¿îȦ 17:20~17:40 Case 5 (µÎ±Ù°Å¸²À¸·Î ³»¿øÇÑ 24¼¼ ³²ÀÚ) ÀåÁöÈÆ(ÀÎÇÏÀÇ´ë)
Åä·Ð 06-11 Áñ°Å¿îȦ 17:40~17:50 Discussion ´Ù°»ç(´Ù¼Ò¼Ó)